AbCellera Biologics Inc vs Baxter International Inc — how do they compare? AbCellera Biologics Inc trades at $9.22 (market cap $2.99B), while Baxter International Inc trades at $27.61 (market cap $14.27B). The key difference: Baxter International Inc is far larger — about 4.8× AbCellera Biologics Inc's market cap, and Baxter International Inc pays a 0.14% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BAX | |
|---|---|---|
Market Cap | $2.99B | $14.27B |
Sector | Health | Health |
52-Week High | $9.76 | $28.35 |
52-Week Low | $2.78 | $15.80 |
Enterprise Value | $2.58B | $21.79B |
Dividend Yield | — | 0.14% |
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →